Glaucoma is the world's first irreversible blinding eye disease and the second leading cause of blindness.Its onset is insidious and its course is long, and if not treated in time, it can eventually lead to blindness.With the increasing population growth and aging, the number of patients with glaucoma is increasing year by year, and the patients' requirements for quality of life are becoming higher and higher, not only to see but to see well, which is a very difficult challenge for the blindness prevention of glaucoma.This paper analyzes the concept and connotation of health management and chronic disease management, and expounds the current research status, problems and challenges, and achievements of glaucoma health management at home and abroad.Combined with the 14th Five-Year Plan (2021—2025) for National Eye Health and other relevant policies and regulations issued in China in recent years, based on industry norms such as the Chinese Glaucoma Guidelines (2020) and various diagnostic and treatment requirements, the development opportunities and solutions for building a glaucoma health management model in accordance with China's national conditions are explored to guide the work of preventing glaucoma blindness, reducing the blindness rate of glaucoma and improving the level of eye health in China.

Glaucoma is the world's first irreversible blinding eye disease and the second leading cause of blindness.Its onset is insidious and its course is long, and if not treated in time, it can eventually lead to blindness.With the increasing population growth and aging, the number of patients with glaucoma is increasing year by year, and the patients' requirements for quality of life are becoming higher and higher, not only to see but to see well, which is a very difficult challenge for the blindness prevention of glaucoma.This paper analyzes the concept and connotation of health management and chronic disease management, and expounds the current research status, problems and challenges, and achievements of glaucoma health management at home and abroad.Combined with the 14th Five-Year Plan (2021—2025) for National Eye Health and other relevant policies and regulations issued in China in recent years, based on industry norms such as the Chinese Glaucoma Guidelines (2020) and various diagnostic and treatment requirements, the development opportunities and solutions for building a glaucoma health management model in accordance with China's national conditions are explored to guide the work of preventing glaucoma blindness, reducing the blindness rate of glaucoma and improving the level of eye health in China.

Objective Aiming to develop a distance-adaptive visual function self-examination system based on tablet computers and evaluate its accuracy.Methods Utilizing ArUco technology on a tablet device equipped with the camera,a system was developed to assess visual functions by identifying QR codes within a 2-meters range for real-time ranging.This system integrates various visual function tests,including visual acuity test(conventional visual acuity test and high-pass visual acuity test with varying contrasts),accommodative amplitude test,and visual field test at the foveal(5°).A total of 22 healthy subjects(44 eyes)participated in visual function assessments,with 6 subjects undergoing visual acuity tests at varying distances(1 m,1.25 m,1.6 m,2 m)and accommodative amplitude tests under both refractive correction and simulated undercorrection of-3.00D.The program distance and actual distance were compared,the consistency of visual acuity outcomes for identical optotype at different distances were assessed,the accommodative amplitude under refractive correction and undercorrection were analyzed,the repeatability of accommodative amplitude outcomes was evaluated using Intraclass Correlation Coefficient(ICC),and the contrast threshold and efficacy of visual field test outcomes were analyzed.Results The program distance and actual distance showed good agreement.High-pass visual acuity tests with the same contrast showed no significant differences at different distances(P?>?0.05),while conventional visual acuity tests showed significant differences at distances of 0.9 to 1.1 meters compared to other distances(P?

Objective:To observe and evaluate the clinical efficacy and safety of albumin-bound paclitaxel as first-line treatment for patients with advanced pancreatic cancer in China, and to explore the prognosis-related molecules in pancreatic cancer based on next-generation sequencing (NGS) of tumor tissues.Methods:From December 2018 to December 2020, patients with locally advanced or metastatic pancreatic cancer were recruited to accept albumin-bound paclitaxel as first-line treatment in the oncology departments of 24 hospitals in East China. The primary endpoints were overall survival (OS) and treatment related adverse events, and the secondary endpoint was progression-free survival (PFS). Adverse effects were graded using Common Terminology Criteria for Adverse Events 5.0 (CTCAE 5.0). NGS sequencing on the primary or metastatic tissue samples of pancreatic cancer obtained through surgical resection or biopsy was performed.Results:This study recruited 229 patients, including 70 patients with locally advanced pancreatic cancer (LAPC) and 159 patients with metastatic pancreatic cancer (mPC). The disease control rate was 79.9% and the objective response rate is 36.3%.The common adverse effects during treatment were anaemia (159 cases), leucopenia (170 cases), neutropenia (169 cases), increased aminotransferases (110 cases), and thrombocytopenia (95 cases), and the incidence of grade 3-4 neutropenia is 12.2% (28/229). The median follow-up time was 21.2 months (95% CI: 18.5-23.1 months). The median PFS (mPFS) was 5.3 months (95% CI: 4.37-4.07 months) and the median OS (mOS) was 11.2 months (95% CI: 9.5-12.9 months). The mPFS of patients with LAPC was 7.4 months (95% CI: 6.6-11.2 months), and their mOS was 15.5 months (95% CI: 12.6-NA months). The mPFS of patients with mPC was 3.9 months (95% CI: 3.4-5.1 months), and their mOS was 9.3 months (95% CI: 8.0-10.8 months). Multivariate Cox regression analysis showed that clinical stage ( HR=1.47, 95% CI: 1.06-2.04), primary tumor site ( HR=0.64, 95% CI: 0.48-0.86), Eastern Cooperative Oncology Group Performance Status (ECOG PS) score ( HR=2.66, 95% CI: 1.53-4.65), and whether to combine radiotherapy ( HR=0.65, 95% CI: 0.42-1.00) were independent influencing factors for the PFS of these patients. The primary tumor site ( HR=0.68, 95% CI: 0.48-0.95), ECOG score ( HR=5.82, 95% CI: 3.14-10.82), and whether to combine radiotherapy ( HR=0.58, 95% CI: 0.35-0.96) were independent influencing factors of the OS of these patients. The most frequent gene mutations in these advanced stage pancreatic patients were KRAS (89.66%), TP53 (77.01%), CDKN2A (32.18%), and SMAD4 (21.84%) by NGS of tumor tissues from 87 pancreatic cancer patients with sufficient specimens. Further analysis revealed that mutations in CDKN2B, PTEN, FGF6, and RBBP8 genes were significantly associated with an increased risk of death ( P＜0.05). Conclusion:Albumin-bound paclitaxel as first-line treatment demonstrated feasible anti-tumor efficacy and manageable safety for patients with advanced pancreatic cancer in China.

Objective:To observe and evaluate the clinical efficacy and safety of albumin-bound paclitaxel as first-line treatment for patients with advanced pancreatic cancer in China, and to explore the prognosis-related molecules in pancreatic cancer based on next-generation sequencing (NGS) of tumor tissues.Methods:From December 2018 to December 2020, patients with locally advanced or metastatic pancreatic cancer were recruited to accept albumin-bound paclitaxel as first-line treatment in the oncology departments of 24 hospitals in East China. The primary endpoints were overall survival (OS) and treatment related adverse events, and the secondary endpoint was progression-free survival (PFS). Adverse effects were graded using Common Terminology Criteria for Adverse Events 5.0 (CTCAE 5.0). NGS sequencing on the primary or metastatic tissue samples of pancreatic cancer obtained through surgical resection or biopsy was performed.Results:This study recruited 229 patients, including 70 patients with locally advanced pancreatic cancer (LAPC) and 159 patients with metastatic pancreatic cancer (mPC). The disease control rate was 79.9% and the objective response rate is 36.3%.The common adverse effects during treatment were anaemia (159 cases), leucopenia (170 cases), neutropenia (169 cases), increased aminotransferases (110 cases), and thrombocytopenia (95 cases), and the incidence of grade 3-4 neutropenia is 12.2% (28/229). The median follow-up time was 21.2 months (95% CI: 18.5-23.1 months). The median PFS (mPFS) was 5.3 months (95% CI: 4.37-4.07 months) and the median OS (mOS) was 11.2 months (95% CI: 9.5-12.9 months). The mPFS of patients with LAPC was 7.4 months (95% CI: 6.6-11.2 months), and their mOS was 15.5 months (95% CI: 12.6-NA months). The mPFS of patients with mPC was 3.9 months (95% CI: 3.4-5.1 months), and their mOS was 9.3 months (95% CI: 8.0-10.8 months). Multivariate Cox regression analysis showed that clinical stage ( HR=1.47, 95% CI: 1.06-2.04), primary tumor site ( HR=0.64, 95% CI: 0.48-0.86), Eastern Cooperative Oncology Group Performance Status (ECOG PS) score ( HR=2.66, 95% CI: 1.53-4.65), and whether to combine radiotherapy ( HR=0.65, 95% CI: 0.42-1.00) were independent influencing factors for the PFS of these patients. The primary tumor site ( HR=0.68, 95% CI: 0.48-0.95), ECOG score ( HR=5.82, 95% CI: 3.14-10.82), and whether to combine radiotherapy ( HR=0.58, 95% CI: 0.35-0.96) were independent influencing factors of the OS of these patients. The most frequent gene mutations in these advanced stage pancreatic patients were KRAS (89.66%), TP53 (77.01%), CDKN2A (32.18%), and SMAD4 (21.84%) by NGS of tumor tissues from 87 pancreatic cancer patients with sufficient specimens. Further analysis revealed that mutations in CDKN2B, PTEN, FGF6, and RBBP8 genes were significantly associated with an increased risk of death ( P＜0.05). Conclusion:Albumin-bound paclitaxel as first-line treatment demonstrated feasible anti-tumor efficacy and manageable safety for patients with advanced pancreatic cancer in China.

Prefoldin (PFDN), a hexameric chaperone complex, is crucial for the correct folding of nascent proteins. PFDN5, a subunit of PFDN, also known as MM-1, plays an essential role in regulating cell migration and senescence. Emerging evidences suggest that PFDN-5 deletion or mutation significantly contributes to the initiation and progression of multiple cancers and the prognosis of patients. In this paper, recent researches on the biological underpinnings of PFDN-5 and its anti-cancer prospect are reviewed, aiming to provide a novel potential therapeutic target for the treatment of malignancies.

Objective To evaluate the clinical effects and safety of paclitaxel liposome or gemcitabine combined with cisplatin in elderly patients with advanced lung squamous cell cancer. Methods A total of 52 elderly patients with advanced lung squamous cell cancer in Kunshan First People's Hospital from January 2012 to October 2016 who received paclitaxel liposome with cisplatin (n=24) or gemcitabine with cisplatin(n = 28) were analyzed retrospectively. The patients received at least 2 cycles of chemotherapy, 2-6 cycles in total. CT was rechecked every 2 cycles. The clinical effects and adverse reactions were evaluated by National Cancer Institute Response Evaluation Criteria in Solid Tumors (NCI RECIST) and NCI Common Terminology Criteria for Adverse Events (NCI CTCAE). Results The objective response rate (ORR) and the disease control rate(DCR)in paclitaxel liposome group and in gemcitabine group had a lot in common [ORR:29.2 %(7/24)vs.32.1 %(9/28),χ2=0.054,P =0.817;DCR:70.8 %(17/24)vs.71.4 %(20/28),χ2=0.002,P =0.962]. The median progression-free survival(PFS) time in gemcitabine group was longer than that in paclitaxel liposome group (5.7 months vs. 5.4 months, χ2= 0.466, P = 0.495). One-year survival rate in gemcitabine group (37.0 %) was higher than that in paclitaxel liposome group (34.8 %) and there was no statistically significant difference (χ 2= 0.027, P = 0.869). However, hematologic adverse reactions in paclitaxel liposome group were lower than those in gemcitabine group (P< 0.05). Conclusion The effect of paclitaxel liposomes combined with cisplatin for treatment of elderly patients with advanced lung squamous cell carcinoma is not inferior to gemcitabine combined with cisplatin, which has less adverse reactions and may be recommended as the first-line chemotherapy for the patients.

Radiotherapy is a major local treatment for cervical cancer.However, local uncontrollability due to radioresistance is still common.Therefore, the prediction of radiosensitivity is quite beneficial to develop an optimal treatment strategy for individual patients.Multiple factors could influence the radiosensitivity of cells, and p53 status is one of them.The upstream or downstream molecules of p53 could also be regulated to affect the radiosensitivity of cervical cancer.The aim of the review is to analyze the difference in p53 status between different types of cervical cancer and to discuss how p53 regulates the response to radiotherapy.

Objective To analyze the therapeutic effect of the radical operation for gastric cancer in elderly patients and to investigate relevant factors affecting the efficacy Methods 216 cases of elderly patients with gastric cancer were divided into two groups:radical distal-and proximal-gastrectomy group (n=108,each).The therapeutic effect in the near future,intraoperative and postoperative recovery,numbers of lymph nodes resection as well as factors affecting the long-term survival rate were compared between two groups.Results The radical distal-versus proximal-gastrectomy group showed that the mean operation time was (241.8 ± 40.2) min vs.(244.7 ± 39.7)min,blood loss was(299.5 ± 114.9) ml vs.(273.8-± 121.4) ml,the number of lymph node dissection was(28.4± 9.4) vs.(27.7 ± 9.1) particles,the complication rate was[14/108 (13.0％)] vs.[15/108 (14.0 ％)],3-year survival rate was (46.9 ％) vs.(47.5 ％),without statistically significant differences (all P ＞ 0.05).Multiple regression analysis showed that TNM stage (OR =1.536),lymph node metastasis(OR =0.739),cancer infiltration depth (OR =1.534) and chemotherapy regimens (OR =1.337)are risk factors for the postoperative 3-year survival rate.Conclusions Surgical treatment of elderly patients with gastric cancer is significantly effective,TNM stage,lymph node metastasis,depth of invasion,tumor size and the chemotherapy regimens are closely associated with the life quality of patients.

Objective To value the clinical efficacy and toxicity of S-1 compared to gemcitabine combined with S-1 in treatment of patients with advanced pancreatic cancer.Methods From January 2011 to December 2013,the data of 46 patients with advanced pancreatic cancer were analyzed retrospectively,including 24 patients receiving S-1 alone (group A) and 22 patients who received gemcitabine combined with S-1 (group B).The results were evaluated by objective response rate (ORR),disease control rate (DCR),survival time and safety.Results In group A the ORR was 20.8 ％ (5/24),DCR was 66.7 ％ (16/24),median progression-free survival was 4.8 months,median overall survival was 9.6 months,and 1 year survival was 12.5 ％.In group B the ORR was 27.3 ％ (6/22),DCR was 72.7 ％ (16/22),median progression-free survival was 5.9 months,median overall survival was 10.3 months,and 1 year survival was 22.7 ％.There was no significant difference between the two groups (P ＞ 0.05).The incidence rates of leukopenia,neutropenia and thrombopenia in group A were significantly lower than those in group B (P ＜ 0.05).Conclusion S-1 alone and gemcitabine combined with S-1 have similar effects in the treatment of advanced pancreatic cancer,but the toxicity of S-1 is mild and tolerable.